Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 17/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624050 | 0.88 | ACACB (0.41) | ACACBHRH3 | |
| SCHEMBL16624097 | 0.86 | ACACB (0.56) | ACACB | |
| SCHEMBL16624049 | 0.85 | CYP17A1 (0.41) | ACACB | |
| SCHEMBL16624024 | 0.85 | SLC6A4 (0.48) | ACACBSLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL18034984 | 0.82 | SLC6A4 (0.57) | ACACBSLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL18033540 | 0.82 | ACACB (0.42) | ACACB | |
| SCHEMBL16624090 | 0.82 | ACACB (0.43) | ACACB | |
| SCHEMBL17993844 | 0.77 | SLC6A2 (0.44) | ACACBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16624039 | 0.77 | DRD1 (0.39) | ACACBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18033541 | 0.77 | HRH3 (0.50) | ACACBSLC6A2SLC6A4SLC6A3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | ACACB 3962/4885SLC6A2 1180/4885SLC6A4 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.